These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 16908121)
1. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Conil JM; Georges B; Breden A; Segonds C; Lavit M; Seguin T; Coley N; Samii K; Chabanon G; Houin G; Saivin S Int J Antimicrob Agents; 2006 Sep; 28(3):226-30. PubMed ID: 16908121 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn. Yang RH; Rong XZ; Hua R; Zhang T Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586 [TBL] [Abstract][Full Text] [Related]
4. [Evaluation of three dosage regimens of amikacin using pharmacokinetic models in patients with cystic fibrosis]. Halacová M; Průsa R; Kotaska K; Vávrová V Cas Lek Cesk; 2004; 143(3):187-90. PubMed ID: 15134039 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Taccone FS; de Backer D; Laterre PF; Spapen H; Dugernier T; Delattre I; Wallemacq P; Vincent JL; Jacobs F Int J Antimicrob Agents; 2011 Jun; 37(6):531-5. PubMed ID: 21489756 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic variability of extended interval tobramycin in burn patients. Bracco D; Landry C; Dubois MJ; Eggimann P Burns; 2008 Sep; 34(6):791-6. PubMed ID: 18395988 [TBL] [Abstract][Full Text] [Related]
7. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes. Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120 [TBL] [Abstract][Full Text] [Related]
8. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. Zazo H; Martín-Suárez A; Lanao JM Int J Antimicrob Agents; 2013 Aug; 42(2):155-60. PubMed ID: 23756322 [TBL] [Abstract][Full Text] [Related]
9. Amikacin pharmacokinetics and the effects of ambient temperature on the dosage regimen in ball pythons (Python regius). Johnson JH; Jensen JM; Brumbaugh GW; Boothe DM J Zoo Wildl Med; 1997 Mar; 28(1):80-8. PubMed ID: 9226620 [TBL] [Abstract][Full Text] [Related]
10. Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis. Yu T; Stockmann C; Healy DP; Olson J; Wead S; Neely AN; Kagan RJ; Spigarelli MG; Sherwin CM J Burn Care Res; 2015; 36(4):e244-52. PubMed ID: 25185930 [TBL] [Abstract][Full Text] [Related]
11. Exploration of once-daily dosing of aminoglycosides through Bayesian simulation. Garrelts JC Pharmacotherapy; 1996; 16(2):286-94. PubMed ID: 8820474 [TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacokinetics of amikacin in Greyhound and Beagle dogs. KuKanich B; Coetzee JF J Vet Pharmacol Ther; 2008 Apr; 31(2):102-7. PubMed ID: 18307501 [TBL] [Abstract][Full Text] [Related]
14. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations. Conil JM; Georges B; Ravat F; Ruiz S; Seguin T; Metsu D; Fourcade O; Saivin S Clin Ther; 2013 Oct; 35(10):1603-12. PubMed ID: 24094465 [TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. Xuan D; Nicolau DP; Nightingale CH Int J Antimicrob Agents; 2004 Mar; 23(3):291-5. PubMed ID: 15164971 [TBL] [Abstract][Full Text] [Related]
16. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin. Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859 [TBL] [Abstract][Full Text] [Related]
17. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. van Zanten AR; Polderman KH; van Geijlswijk IM; van der Meer GY; Schouten MA; Girbes AR J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients. Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366 [TBL] [Abstract][Full Text] [Related]
19. [Assessment of pharmacokinetic parameters of amikacin in a group of neutropenic patients in onco-hematology]. Pivot-Dumarest C; Deweerdt C; Troncy J; Sorensen P; Roux D; Maire P Pathol Biol (Paris); 1996 Apr; 44(4):299-305. PubMed ID: 8763595 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance. Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]